XML 33 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727
Collaborative Arrangements and Licensing Agreements, Traditional Pharmaceutical Alliances and Licensing - Biogen Idec (ISIS-SMN) (Details) - Biogen Idec [Member]
$ in Millions
1 Months Ended 6 Months Ended
Jul. 31, 2015
USD ($)
Jan. 31, 2012
USD ($)
Jun. 30, 2015
USD ($)
Agreement
ISIS-SMN [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Cumulative payments received     $ 110.0
Next prospective milestone     11.0
ISIS-SMN [Member] | Phase 3 Study in Infants with SMA [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Milestone payment earned     9.0
ISIS-SMN [Member] | Open-Label Extension Study in Children with SMA [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Milestone payment earned     7.0
ISIS-SMN [Member] | Phase 3 Study in Infants and Phase 2 Study in Children with SMA [Member] | Subsequent Event [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Milestone payment earned $ 10.7    
ISIS-SMN [Member] | License Fee and Substantive Milestones [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Maximum amount of payments receivable     346.0
ISIS-SMN [Member] | Development Milestones [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Maximum amount of payments receivable     121.0
ISIS-SMN [Member] | Regulatory Milestones [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Maximum amount of payments receivable     $ 150.0
Collaborations and Licensing Agreements [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Number of collaborative agreements | Agreement     4
Agreement Entered into in January 2012 [Member] | ISIS-SMN [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Upfront fee recorded as deferred revenue   $ 29.0